SIMTRIYO
Jul 31, 2026
Otsuka’s SIMTRIYO Approval Opens Up a Brand-New ADHD Drug Class
Summary FDA approved Otsuka’s SIMTRIYO (centanafadine) on July 24, 2026, for ADHD treatment in patients aged ≥6 years weighing at least 20 kg. First-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), introducing a novel triple-mechanism approach. Approval backed by four Phase 3 trial...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
